AGMT Austrian CLL (Chronic Lymphocytic Leukemia) Registry - Trial NCT06250465

Timeline & Enrollment

Primary Outcome

General Characteristics,Genetic Profiling,Proportion of CLL patients in Austria that require treatment,Number of patients with concomitant diseases,Number and type of treatment,Patient Outcome,Toxicities

Summary

For until very recently CLL has been considered an uncurable disease, with the only few
 exceptions of a part of patients capable of undergoing and successfully standing allogeneic
 stem cell transplant. However, the introduction of chemoimmunotherapy in particular the FCR
 (fludarabine, cyclophosphamide, rituximab) regimen has established a relevant population of
 IgVH mutated patients, who remain relapse-free for up to 10 years with a clear plateau at
 this level. However, for the largest proportion of all CLL patients the disease is still
 associated with a reduction in life expectancy as compared to a matched population.
 
 The field has made further substantial progress by the introduction of BTK inhibitors and
 Bcl2 inhibitors, novel antibodies as well as by the understanding of the role of minimal
 residual disease (MRD), mutations and their clonal evolution over time as risk factors and
 factors governing the kind and duration of therapy.
 
 Due to the limited follow up of frontline therapy trials using novel drugs, it is not yet
 clear, what the long-term results with many of the new drugs will be. Particularly, long-term
 PFS, the potential for cure and the long-term safety issues remain relevant parameters
 requiring examination, as are infections, interactions with other drugs or quality of life
 issues.
 
 CLL has not been systematically assessed in Austria to date. This medical registry of the
 AGMT is thus the first Austrian-wide standardized documentation of this disease.

ICD-10 Classifications